Side-by-side comparison of AI visibility scores, market position, and capabilities
Avise provides specialized diagnostic tests for autoimmune diseases including lupus and rheumatoid arthritis that help rheumatologists make faster and more accurate diagnoses.
Avise Medical is a specialty diagnostics company founded in 2012 that develops laboratory tests specifically designed to help rheumatologists diagnose and monitor autoimmune diseases including lupus, rheumatoid arthritis, and related conditions. The company's flagship products include AVISE Lupus, a panel of blood biomarkers that increases diagnostic accuracy for systemic lupus erythematosus compared to traditional single-marker tests, and AVISE CTD for connective tissue disease diagnosis. Autoimmune diseases are notoriously difficult to diagnose because symptoms overlap with many other conditions and individual biomarkers have limited sensitivity and specificity. Avise addresses this through multi-biomarker panels that use machine learning to combine signals into diagnostic scores with better performance characteristics. The company works directly with rheumatology practices and provides specialized clinical interpretation support for complex cases. Avise raised over $100M and expanded its diagnostic portfolio to cover monitoring of disease activity and treatment response in addition to initial diagnosis. The company represents the application of advanced biomarker discovery and machine learning to specialty diagnostics in rheumatology.
$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.
ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.